About Xceleron
Xceleron is a Healthcare company based in Germantown (United States) founded in 1997, and was acquired by Pharmaron in January 2017. Accelerator Mass Spectrometry is utilized by Xceleron for pharmaceutical analysis. Xceleron has raised $10.02 million across 5 funding rounds from investors including Pharmaron, Montgomery County Government and Albion Capital. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Analytical Testing. Its competitors include Evelo Biosciences, PathogenDX and BioAgilytix; 2 of its 3 listed competitors have raised funding.
Company details
Xceleron was founded in 1997 in Germantown, United States, as an analytical contract research organization focused on the pharmaceutical sector. Accelerator Mass Spectrometry technology is applied by the company to support preclinical and clinical drug development, enabling analysis of small samples for absolute bioavailability, pharmacokinetics, and tissue distribution studies. Acquisition by Pharmaron occurred in January 2017, integrating services into broader preclinical and clinical offerings.
- Headquarters Germantown, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website xceleron.com
- Social LinkedIn X
- Acquired by Pharmaron (Jan 2017)
Funding Insights of Xceleron
Xceleron has successfully raised a total of $10.02M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $2.4 million completed in February 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.02M
- Total Rounds 5
- Last Round Series C — $2.4M
- First Round $3.66M
(May 2005)
- Investors Count 6
All 5 funding rounds of Xceleron with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2012 | $2.4M | Series C | – | – | |
| Jan 2010 | Series C | – | – | ||
| Mar 2007 | Grant | – | – | ||
| Dec 2006 | $3.96M | Series B | – | – | |
| May 2005 | $3.66M | Series A | – | – |
7 investors in total: 7 institutional.
Investors in Xceleron
Xceleron has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Pharmaron, Montgomery County Government and Albion Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Tech and Offline focused Stage-Agnostic micro VC Firm investing in the UK | solonventures.com | London, United Kingdom | ||
Venture capital investments are managed by Albion Capital. | 1996 | albion.capital | London, United Kingdom | |
Venture capital firm investing in European software scale-up companies | frogcapital.com | London, United Kingdom | ||
| foursome.co.uk | ||||
County government services and public information are provided to residents. | 1776 | montgomerycountymd.gov | United States | |
| closeventures.co.uk | ||||
Drug discovery and development services for small molecules are provided. | 2003 | pharmaron.com | Beijing, China |
Investor details for Xceleron
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Xceleron
4 dated milestones of Xceleron across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Xceleron is founded.
- Funding First funding round of $3.7M.
- Funding Latest funding round, Series C, of $2.4M.
- Exit Acquired by Pharmaron.
Competitors of Xceleron
Xceleron has 3 listed competitors in our database, 2 of them funded. They include Evelo Biosciences, PathogenDX and BioAgilytix.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| evelobio.com | 2015 | Cambridge, United States | $166.5M | 117 | Therapeutics for inflammatory diseases, COVID-19, and cancer are developed. | |
| pathogendx.com | 2014 | Tucson, United States | $11.58M | 31 | Provider of DNA-based pathogen testing kits | |
| bioagilytix.com | 2008 | Durham, United States | 446 | Large-molecule bioanalysis is provided for biologics and biosimilars development. |
Detailed competitors of Xceleron
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Xceleron (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xceleron
Complete news archive for Xceleron
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Xceleron
Xceleron was founded in 1997 and raised its 1st funding round 8 years after it was founded.
Xceleron is headquartered in Germantown, United States.
Xceleron is a funded company, having raised a total of $10.02M across 5 funding rounds to date. The company's 1st funding round was a Series A of $3.66M, raised on May 2005.
Xceleron was founded in 1997 in Germantown, United States, as an analytical contract research organization focused on the pharmaceutical sector. Accelerator Mass Spectrometry technology is applied by the company to support preclinical and clinical drug development, enabling analysis of small samples for absolute bioavailability, pharmacokinetics, and tissue distribution studies. Acquisition by Pharmaron occurred in January 2017, integrating services into broader preclinical and clinical offerings.
Xceleron's top competitors include PathogenDX, BioAgilytix and Evelo Biosciences.
Xceleron has 7 investors. Key investors include Pharmaron, Montgomery County Government, Albion Capital, Solon Ventures, and Frog Capital.
Yes. Xceleron was acquired by Pharmaron in January 2017.